Tirzepatide has recently been approved for this purpose and its safety and efficacy have been assessed in multiple RCTs, where results suggest a significant reduction in HbA1c as well as body weight in comparison to placebo (112), Semaglutide (113), insulin degludec (114), insulin Glargine (115, 116) and similar safety profile to GLP- receptor agonists and a lesser incidence of hypoglycemia in comparison to insulin or sulfonylureas in the above studies. The gene discussed is INS; the disease is Hypoglycemia.